| 영문 | mammary papilla, nipple | 한글 | 유두, 젖꼭지 |
|---|---|---|---|
| 설명 | 젖샘에서 만들어진 모유가 나오는 통로에 해당. |
||
| 영문 | mammary glands | 한글 | 젖샘, 유선 |
|---|---|---|---|
| 설명 | 정상적으로 아기를 낳은 산모에서는 뇌에서 젖분비호르몬(prolactin)의 분비가 증가하여 젖샘에서 젖을 만들게 된다. 이 때 젖의 분비를 촉진시키는 것으로는 아기가 젖을 빠는 행위 등이 있으며, 젖샘에서 생산된 모유는 젖샘관을 거쳐 젖꼭지를 통해 밖으로 나가게 된다. |
||
| 영문 | thymus(gland) | 한글 | 가슴샘 |
|---|---|---|---|
| 설명 | 가슴의 앞 위쪽에 위치한 림프성 장기로서, 사춘기에 최고의 무게에 달했다가 이후에 퇴축한다. 이것은 세포매개 면역(cell-mediated immunity: 주로 T-림프구에 의해 일어나며, 자기와 다른 세포에 대한 인식과 이식거부반응에 관여함)기능의 발달과 성숙에 필요한 장기이며, 회백적색으로 보통 정중면에서 결합조직에 의해 결합된 두 개의 엽으로 되어 있다. 가슴샘은 상피세포, 림프구, 가슴샘세포로 구성되어 있으며 전구세포가 가슴샘에 이행하여 림프구로 분화되고, 그 대부분은 파괴되나 나머지는 T림프구를 형성한다. 가슴샘은 또한 호르몬 유사물질인 thymine, thymopoietin, thymosin 등을 분비한다. |
||
| 영문 | thyroid gland | 한글 | 갑상샘 |
|---|---|---|---|
| 설명 | 사람의 몸에서 가장 큰 내분비샘으로 목의 앞쪽, 아래쪽에 위치하고 있으며 2엽으로 구성되어 있다. 각 엽은 기관의 양쪽에 있으며 좁은 잘룩에 의해 앞에서 연결되어 있다. 갑상샘호르몬인 티록신(thyroxine)을 분비하고 저장하며, 필요에 따라 방출한다. 또한 갑상샘은 티로칼시토닌(thyrocalcitonin)도 분비한다. 병적인 상태에서 크기가 대개 증가하고, 일부에서는 도리어 위축되며, 통증을 나타내기도 한다. |
||
| 영문 | parotid gland | 한글 | 귀밑샘, 이하선 |
|---|---|---|---|
| 설명 | 침샘의 하나. 침샘이란, 음식을 삼킬 때 입안으로 분비되어 음식물이 잘게 씹히는데 도움을 주며, 음식물을 소화하는데 이용되는 효소를 가지고 있는 침을 생산하는 곳을 말함. 크게 3가지의 침샘을 가지고 있으며, 위치와 모양은 옆의 그림과 같다.  |
||
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| MTV | mammary tumor virus; metatarsus varus; mouse mammary tumor virus |
| biol | biology, biological |
| CIN | Cervical Intraepithelial Neoplasia |
| CIN | central inhibition; cervical intraepithelial neoplasia; chronic interstitial nephritis |
| MG | mammary gland |
|---|---|
| AIN | Anal intraepithelial neoplasia |
| CIN | Cervical Intraephithelial Neoplasia |
| CIN 3 | Cervical Intraepithelial Neoplasia grade 3 |
| CIN III | Cervical intraepithelial neoplasia grade III |
| body of mammary gland | The principal part of the breast, consisting of glandular tissue and its supporting fibrous tissue. It forms a conical mass converging toward the nipple and is surrounded by adipose tissue. Synonym: corpus mammae. (05 Mar 2000) |
|---|---|
| mammary gland | <anatomy> Milk producing gland of female mammals. An adapted sweat gland, it is made up of milk producing alveolar cells, surrounded by contractile myoepithelial cells, together with considerable numbers of fat cells. Milk production is hormonally controlled. (18 Nov 1997) |
| venous circle of mammary gland | areolar venous plexus |
| lobes of mammary gland | The 15 to 20 separate portions of the mammary gland that radiate from the central area deep to the nipple like wheel spokes and comprise the body of the mammary gland; each is drained by a single lactiferous duct. Synonym: lobi glandulae mammariae. (05 Mar 2000) |
| lobules of mammary gland | Subdivisions of the lobes of the mammary gland. Synonym: lobuli glandulae mammariae. (05 Mar 2000) |
| cervical intraepithelial neoplasia | A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| prostatic intraepithelial neoplasia | A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|